These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 39371371)
1. Beyond Fentanyl Test Strips: Investigating Other Urine Drug Test Strips for Drug Checking Applications. Sisco E; Appley MG; Pyfrom EM; Banta-Green CJ; Shover CL; Molina CA; Biamont B; Robinson EL Forensic Chem; 2024 Sep; 40():. PubMed ID: 39371371 [TBL] [Abstract][Full Text] [Related]
2. Understanding sensitivity and cross-reactivity of xylazine lateral flow immunoassay test strips for drug checking applications. Sisco E; Nestadt DF; Bloom MB; Schneider KE; Elkasabany RA; Rouhani S; Sherman SG Drug Test Anal; 2024 Sep; 16(9):942-947. PubMed ID: 38043944 [TBL] [Abstract][Full Text] [Related]
3. The Detection of Xylazine in Tijuana, Mexico: Triangulating Drug Checking and Clinical Urine Testing Data. Friedman JR; Montoya AG; Ruiz C; Tejeda MAG; Segovia LA; Godvin ME; Sisco E; Pyfrom EM; Appley MG; Shover CL; Bufanda LP medRxiv; 2024 Aug; ():. PubMed ID: 39228694 [TBL] [Abstract][Full Text] [Related]
4. An urgent need for community lot testing of lateral flow fentanyl test strips marketed for harm reduction in Northern America. Lieberman M; Badea A; Desnoyers C; Hayes K; Park JN Harm Reduct J; 2024 Jun; 21(1):115. PubMed ID: 38877522 [TBL] [Abstract][Full Text] [Related]
5. Implementation and Uptake of the Massachusetts Drug Supply Data Stream: A Statewide Public Health-Public Safety Partnership Drug Checking Program. Green TC; Olson R; Jarczyk C; Erowid E; Erowid F; Thyssen S; Wightman R; Del Pozo B; Michelson L; Consigli A; Reilly B; Ruiz S J Public Health Manag Pract; 2022 Nov-Dec 01; 28(Suppl 6):S347-S354. PubMed ID: 36194805 [TBL] [Abstract][Full Text] [Related]
6. Barriers to, and Facilitators of, Checking Drugs for Adulterants in the Era of Fentanyl and Xylazine: Qualitative Study. Aronson ID; Ardouin-Guerrier MA; Baus JE; Bennett AS JMIR Form Res; 2024 Jul; 8():e56755. PubMed ID: 38959505 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of fentanyl immunoassay test strips for rapid in-situ detection of fentanyl and fentanyl analogs in seized samples and alternative matrices. Norman C; Marland V; McKenzie C; Ménard H; Nic Daéid N Int J Drug Policy; 2023 Aug; 118():104102. PubMed ID: 37343365 [TBL] [Abstract][Full Text] [Related]
8. Nitazene test strips: a laboratory evaluation. De Vrieze LM; Stove CP; Vandeputte MM Harm Reduct J; 2024 Aug; 21(1):159. PubMed ID: 39198843 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the sensitivity, stability, and cross-reactivity of commercial fentanyl immunoassay test strips. Rodriguez-Cruz SE J Forensic Sci; 2023 Sep; 68(5):1555-1569. PubMed ID: 37420315 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of fentanyl in methamphetamine and cocaine samples collected by community-based drug checking services. Wagner KD; Fiuty P; Page K; Tracy EC; Nocera M; Miller CW; Tarhuni LJ; Dasgupta N Drug Alcohol Depend; 2023 Nov; 252():110985. PubMed ID: 37826988 [TBL] [Abstract][Full Text] [Related]
11. Costing analysis of a point-of-care drug checking program in Rhode Island. Cepeda JA; Thompson E; Ujeneza M; Tardif J; Walsh T; Morales A; Rosen JG; Green TC; Park JN Drug Alcohol Depend; 2023 Dec; 253():111028. PubMed ID: 38000322 [TBL] [Abstract][Full Text] [Related]
12. Testing the test strips: laboratory performance of fentanyl test strips. Halifax JC; Lim L; Ciccarone D; Lynch KL Harm Reduct J; 2024 Jan; 21(1):14. PubMed ID: 38238757 [TBL] [Abstract][Full Text] [Related]
13. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. Green TC; Park JN; Gilbert M; McKenzie M; Struth E; Lucas R; Clarke W; Sherman SG Int J Drug Policy; 2020 Mar; 77():102661. PubMed ID: 31951925 [TBL] [Abstract][Full Text] [Related]
14. Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada. Klaire S; Janssen RM; Olson K; Bridgeman J; Korol EE; Chu T; Ghafari C; Sabeti S; Buxton JA; Lysyshyn M Int J Drug Policy; 2022 Aug; 106():103741. PubMed ID: 35671687 [TBL] [Abstract][Full Text] [Related]
15. High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips. Lockwood TE; Vervoordt A; Lieberman M Harm Reduct J; 2021 Mar; 18(1):30. PubMed ID: 33750405 [TBL] [Abstract][Full Text] [Related]
16. A lot testing protocol for quality assurance of fentanyl test strips for harm reduction applications. Fernando H; Amate A; Hayes KL; Whitehead HD; Desnoyers C; Uzobuife E; Denchfield MS; Whitelatch B; Lieberman M Harm Reduct J; 2024 Aug; 21(1):152. PubMed ID: 39169393 [TBL] [Abstract][Full Text] [Related]
17. Assessing the limit of detection of Fourier-transform infrared spectroscopy and immunoassay strips for fentanyl in a real-world setting. McCrae K; Tobias S; Grant C; Lysyshyn M; Laing R; Wood E; Ti L Drug Alcohol Rev; 2020 Jan; 39(1):98-102. PubMed ID: 31746056 [TBL] [Abstract][Full Text] [Related]
18. Evaluating fentanyl test strips as a harm reduction strategy in rural and urban counties: study protocol for a randomized controlled trial. Short Mejia A; Smith GA; Fernandez SA; Freisthler B; Grella C; Michaels NL Trials; 2024 Sep; 25(1):587. PubMed ID: 39232778 [TBL] [Abstract][Full Text] [Related]
19. Enhancing drug checking services for supply monitoring: perspectives on implementation in syringe service programs in the USA. Moon KJ; Whitehead HD; Trinh A; Hasenstab KA; Hayes KL; Stanley D; Carter B; Barclay R; Lieberman M; Nawaz S Harm Reduct J; 2024 Jan; 21(1):11. PubMed ID: 38218980 [TBL] [Abstract][Full Text] [Related]
20. Perspectives of people in Philadelphia who use fentanyl/heroin adulterated with the animal tranquilizer xylazine; Making a case for xylazine test strips. Reed MK; Imperato NS; Bowles JM; Salcedo VJ; Guth A; Rising KL Drug Alcohol Depend Rep; 2022 Sep; 4():100074. PubMed ID: 36846574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]